Selected High-Risk Patients With Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy for Adjuvant Chemotherapy: A Multi-Institutional Retrospective Study

被引:17
作者
Ikeda, Masaomi [1 ,2 ]
Matsumoto, Kazumasa [1 ]
Hirayama, Takahiro [1 ]
Koguchi, Dai [3 ]
Murakami, Yasukiyo [4 ]
Matsuda, Daisuke [5 ]
Okuno, Norihiko [6 ]
Utsunomiya, Takuji [4 ]
Taoka, Yoshinori [3 ]
Irie, Akira [2 ]
Iwamura, Masatsugu [1 ]
机构
[1] Kitasato Univ, Sch Med, Dept Urol, Sagamihara, Kanagawa, Japan
[2] Kitasato Univ, Kitasato Inst Hosp, Dept Urol, Tokyo, Japan
[3] Kitasato Univ, Med Ctr, Dept Urol, Saitama, Japan
[4] Sagamihara Kyodo Hosp, Kanagawa Prefectural Federat Agr Cooperat Hlth &, Dept Urol, Sagamihara, Kanagawa, Japan
[5] Higashiyamato Hosp, Dept Urol, Tokyo, Japan
[6] Natl Hosp Org Sagamihara Hosp, Dept Urol, Sagamihara, Kanagawa, Japan
关键词
Lymph node status; Lymphovascular invasion; pT stage; Surgical margin; Tumor grade; UPPER URINARY-TRACT; TRANSITIONAL-CELL CARCINOMA; BLADDER-CANCER; MICROSATELLITE INSTABILITY; TUMORS; OUTCOMES;
D O I
10.1016/j.clgc.2017.10.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We investigated the efficacy of adjuvant chemotherapy (AC) in patients with upper tract urothelial carcinoma (UTUC) and determined those who qualified for AC. In multivariate analyses, 5 factors (>= pT3, pN+, G3, lymphovascular invasion, positive surgical margin) were independently predictive of poorer survival. Having more than 3 risk factors defined the high-risk group. AC was associated with improved survival in high-risk UTUC. Background: No definitive evidence exists regarding use of adjuvant chemotherapy (AC) for high-risk cases after radical nephroureterectomy (RNU), and the benefit of AC remains controversial. The aims of this study were to evaluate the efficacy of AC in patients with upper tract urothelial carcinoma (UTUC) and to determine those who qualified for AC. Patients and Methods: From 1990 to 2015, 449 patients with nonmetastatic UTUC underwent RNU at 6 Kitasato University-affiliated hospitals. Eight patients who received neoadjuvant chemotherapy were excluded from this study. One hundred patients (23%) received platinum-based AC for a median of 3 courses. Disease-free survival and cancer-specific survival (CSS) were estimated using the Kaplan-Meier method. Multivariate analyses were performed with the Cox proportional hazards regression model, controlling for the effects of clinicopathological factors. Results: The median age was 69 years, and the median follow-up period was 35.7 months. In multivariate analyses, factors independently predictive of poorer survival included pT stage (>= pT3), lymph node status (pN+), tumor grade (Grade 3), lymphovascular invasion, and soft tissue surgical margin. For the risk stratification model, patients were categorized into 3 groups on the basis of these 5 risk factors. In the high-risk group (at least 3 risk factors, 83 patients), 41 patients (49%) were treated with AC, and the 5-year CSS rate was higher in the AC group compared with the non-AC group (P = .02). Conclusion: Having more than 3 risk factors defined the high-risk group among UTUC patients after RNU. AC was associated with improved CSS in patients with high-risk UTUC. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:E669 / E675
页数:7
相关论文
共 23 条
[1]  
Advanced Bladder Cancer ( ABC), 2005, EUR UROL, V48, P202, DOI DOI 10.1016/J.EURUR0.2005.04.006
[2]   Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review [J].
Aziz, Atiqullah ;
Dobruch, Jakub ;
Hendricksen, Kees ;
Kluth, Luis A. ;
Necchi, Andrea ;
Noon, Aidan ;
Rink, Michael ;
Roghmann, Florian ;
Seiler, Roland ;
Gontero, Paolo ;
Kassouf, Wassim ;
Shariat, Shahrokh F. ;
Xylinas, Evanguelos .
WORLD JOURNAL OF UROLOGY, 2017, 35 (09) :1401-1407
[3]   Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: A study by the Hellenic Cooperative Oncology Group [J].
Bamias, A ;
Deliveliotis, C ;
Fountzilas, G ;
Gika, D ;
Anagnostopoulos, A ;
Zorzou, MP ;
Kastritis, E ;
Constantinides, C ;
Kosmidis, P ;
Dimopoulos, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2150-2154
[4]   TIME TO DEFINE AN INTERNATIONAL STANDARD OF POSTOPERATIVE CARE FOR RESECTED UPPER URINARY TRACT TRANSITIONAL CELL CARCINOMA (TCC) - OPENING OF THE PERI-OPERATIVE CHEMOTHERAPY VERSUS SURVEILLANCE IN UPPER TRACT UROTHELIAL CANCER (POUT) TRIAL [J].
Birtle, Alison J. ;
Lewis, Rebecca ;
Johnson, Mark ;
Hall, Emma .
BJU INTERNATIONAL, 2012, 110 (07) :919-921
[5]   Distinct patterns of microsatellite instability are seen in tumours of the urinary tract [J].
Catto, JWF ;
Azzouzi, AR ;
Amira, N ;
Rehman, I ;
Feeley, KM ;
Cross, SS ;
Fromont, G ;
Sibony, M ;
Hamdy, FC ;
Cussenot, O ;
Meuth, M .
ONCOGENE, 2003, 22 (54) :8699-8706
[6]   Predicting Clinical Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma [J].
Cha, Eugene K. ;
Shariat, Shahrokh F. ;
Kormaksson, Matthias ;
Novara, Giacomo ;
Chromecki, Thomas F. ;
Scherr, Douglas S. ;
Lotan, Yair ;
Raman, Jay D. ;
Kassouf, Wassim ;
Zigeuner, Richard ;
Remzi, Mesut ;
Bensalah, Karim ;
Weizer, Alon ;
Kikuchi, Eiji ;
Bolenz, Christian ;
Roscigno, Marco ;
Koppie, Theresa M. ;
Ng, Casey K. ;
Fritsche, Hans-Martin ;
Matsumoto, Kazumasa ;
Walton, Thomas J. ;
Ehdaie, Behfar ;
Tritschler, Stefan ;
Fajkovic, Harun ;
Martinez-Salamanca, Juan I. ;
Pycha, Armin ;
Langner, Cord ;
Ficarra, Vincenzo ;
Patard, Jean-Jacques ;
Montorsi, Francesco ;
Wood, Christopher G. ;
Karakiewicz, Pierre I. ;
Margulis, Vitaly .
EUROPEAN UROLOGY, 2012, 61 (04) :818-825
[7]   The World Health Organization International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder [J].
Epstein, JI ;
Amin, MB ;
Reuter, VR ;
Mostofi, FK .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1998, 22 (12) :1435-1448
[8]  
Greene F., 2002, AJCC cancer staging handbook: From the AJCC cancer staging manual, V6th
[9]   Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [J].
Grossman, HB ;
Natale, RB ;
Tangen, CM ;
Speights, VO ;
Vogelzang, NJ ;
Trump, DL ;
White, RWD ;
Sarosdy, MF ;
Wood, DP ;
Raghavan, D ;
Crawford, ED .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (09) :859-866
[10]  
Hartmann A, 2002, CANCER RES, V62, P6796